I Williams*1, D Asboe2, A Babiker3, R Goodall3, M Hooker3, and FORTE Trial Steering Committee
1Royal Free and Univ. Coll. Med. Sch., London UK; 2Chelsea and Westminster Hosp., London, UK; and 3MRC Clin. Trials Unit, London UK
D V Havlir*1,2, R Bassett2,3, XD Li2,4, R Pollard2,4, D Richman2,5, A Collier2,6, P Tebas2,7, M Hirsch2,8, M Strain5, C C Ignacio5, and J K Wong5
1Univ. of California, San Francisco, USA; 2ACTG; 3Harvard Sch. of Publ. Hlth., Boston, MA, USA; 4Univ. of California, Davis, USA; 5Univ. of California and VASDHS, San Diego, USA; 6Univ. of Washington, Seattle, USA; 7Univ. of Pennsylvania, Philadelphia, USA; and 8Harvard Univ., Boston, MA, USA
A Barrios*1, E Negredo2, J Vilaró-Rodríguez3, P Domingo3, V Estrada4, P Labarga5, V Asensi6, D Morales7, J Santos8, J Terrón9, E Casas10, M Riera11, A Vergara12, J Gonzalez-Lahoz1, V Soriano1, and ddI+TDF+EFV Spanish Study Group
1Hosp. Carlos III, Madrid, Spain; 2Hosp. Germans Trias i Pujol, Barcelona, Spain; 3Hosp. Sant Pau, Barcelona, Spain; 4Hosp. Clin. San Carlos, Madrid, Spain; 5Hosp. de San Millán, Logrońo, Spain; 6Asturias Central Hosp., Oviedo, Spain; 7Hosp. Virgen de la Macarena, Sevilla, Spain; 8Hosp. Virgen de la Victoria, Málaga, Spain; 9Hosp. de Jerez, Cádiz, Spain; 10Hosp. Príncipe de Asturias, Madrid, Spain; 11Hosp. Son Dureta, Palma de Mallorca, Spain; and 12Hosp. de Puerto Real, Cádiz, Spain
A L Rendon*, M Nunez, D Gonzalez-Requena, I Jimenez-Nacher, J Gonzalez-Lahoz, and V Soriano
Hosp. Carlos III, Madrid, Spain
C Fagard1, J Ananworanich1, M Le Braz1, S Saenawat2, S Wicharuk2, T Perneger1, L Perrin1, D Cooper3, M Cavassini4, C Ebnöther5, D Genné6, P Vernazza7, E Bernasconi8, R Nuesch9, and B Hirschel*1
1Univ. Hosp. Geneva, Switzerland; 2HIVNAT, Bangkok, Thailand; 3Natl. Ctr. in HIV Epidemiology and Clin. Res., Univ. of New South Wales, Sydney, Australia; 4CHUV, Lausanne, Switzerland; 5Univ. Hosp. Zurich, Switzerland; 6Hosp. de La Chaux de Fonds, Switzerland; 7Kantonsspital St. Gallen, Switzerland; 8Hosp. Civico, Lugano, Switzerland; and 9Univ. Hosp., Basel, Switzerland
I Pellegrin*1, R Thiébaut2, P Blanco1, P Merel1, J F Viallard1, M H Schrive1, H J Fleury1, J F Moreau1, and J L Pellegrin1
1Bordeaux Univ. Hosp., France and 2INSERM EO338, Bordeaux Univ. Hosp., France
J Gathe*1, D Podzamczer2, M Johnson3, R Schwartz4, V Yeh5, N Travers6, K Luff6, R Tressler6, and S Brun6
1Therapeutic Concepts, P.A., Houston, TX, USA; 2Hosp. de Bellvitge, Barcelona, Spain; 3Royal Free Hosp., London, UK; 4Private Practice, Fort Myers, FL, USA; 5AIDS Healthcare Fndn., Los Angeles, CA, USA; and 6Abbott Labs., Abbott Park, IL, USA
